Prognostic value of myocardial perfusion scintigraphy in type 2 diabetic patients with mild, stable angina pectoris by Wiersma, Jacobijne J. et al.
ORIGINAL ARTICLE
Prognostic value of myocardial perfusion
scintigraphy in type 2 diabetic patients
with mild, stable angina pectoris
Jacobijne J. Wiersma, MD, PhD,
a Hein J. Verberne, MD, PhD,
b Wik L. ten Holt,
MD,
c Ineke M. Radder,
a Lea M. Dijksman, MSc,
a Berthe L. F. van Eck-Smit, MD,
PhD,
b Mieke D. Trip, MD, PhD,
a Jan G. P. Tijssen, PhD,
a and Jan J. Piek, MD, PhD
a
Aim. To determine the prognostic value of reversible myocardial perfusion defects on
myocardial perfusion scintigraphy (MPS) in patients with type 2 diabetes mellitus and mild
anginal complaints.
Methods and results. In the MERIDIAN trial, patients with diabetes mellitus type 2, stable,
mild anginal symptoms (Canadian Cardiovascular Society classiﬁcation (CCS) I-II/IV) and
reversible perfusion defects were randomized to either continued pharmacological treatment or
early invasive treatment. In this sub analysis, the severity of the myocardial perfusion defect
was related to the occurrence of cardiac death and non-fatal myocardial infarction, in 319
patients (63% male, 65 ± 9 years). During follow-up (2.2 ± 0.6 years), 14 patients had a cardiac
event: 3 in 171 patients without myocardial ischemia and 11 in 148 patients with myocardial
ischemia. Annual event rates rose from 0.8% to 5.8% with increasing severity of myocardial
ischemia. Multivariable analysis identiﬁed the presence of severe myocardial ischemia (hazard
ratio (HR) 5.45, 95%CI 1.89-15.71) and insulin use (HR 4.00, 95%CI 1.25-12.75) as independent
predictors of cardiac events.
Conclusions. Type 2 diabetics with mild anginal symptoms with no or moderate myo-
cardial ischemia have a low annual cardiac event rate. In patients with severe myocardial
ischemia event rate increased 3-6 fold. (J Nucl Cardiol 2009;16:524–32.)
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INTRODUCTION
To date, approximately 150 million people world-
wide are diagnosed with type 2 diabetes mellitus and
this number is expected to double before 2025.
1 Diabetic
patients are at a 2-4 fold higher risk of coronary artery
disease (CAD).
2 Furthermore, in diabetics CAD devel-
ops at a younger age and, when CAD becomes overt,
these patients have a poor cardiovascular prognosis.
2-4
Finally, approximately 75% of patients with diabetes
mellitus type 2 will die from a cardiac cause.
4
Patients with diabetes mellitus are more likely to
have an atypical or less distinct expression of their
anginal symptoms. Myocardial ischemia is already
present in ±20% of asymptomatic patients with type 2
diabetes mellitus.
5 Early recognition of CAD is war-
ranted to install dietary and lifestyle adaptation,
pharmacological risk factor modiﬁcation and optimiza-
tion of anti-anginal treatment.
Several (sub)-studies have reported on the prog-
nostic value of myocardial perfusion defects on MPS in a
variety of diabetic patients. However, limited informa-
tion is available on the signiﬁcance of myocardial
ischemia as assessed with MPS in type 2 diabetic patients
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524with mild anginal complaints (Canadian Cardiovascular
Society classiﬁcation (CCS) I-II/IV).
6-8 Therefore, the
purpose of this study was to determine the prognostic
value of myocardial ischemia, as assessed with myo-
cardial perfusion scintigraphy (MPS), in a well-deﬁned
patient population with type 2 diabetes mellitus and mild,
stable anginal complaints (CCS I-II/IV).
METHODS
Setting
This study consisted of 319 patients who underwent a
MPS to establish eligibility for the randomized multicenter
MERIDIAN trial (Multicenter trial of Early Revascularization
In patients withDIabetes mellitus and mild ANginal symptoms)
at the Cardiology and Internal Medicine out-patient clinics of
26 Dutch hospitals (see Appendix for participating centers).
Detailed descriptions of the study design and of the principal
results have been published previously.
9 The aim of the
MERIDIAN trial was to investigate if an early coronary
revascularization strategy would reduce cardiovascular com-
plications in patients with type 2 diabetes mellitus and mild,
stable anginal symptoms (CCS I-II/IV). Only patients with
myocardial ischemia as assessed with MPS were eligible for
randomization toan early invasive approach including coronary
angiography and revascularization if feasible or a continued
pharmacological treatment. Patients without myocardial
ischemia on MPS were treated according to local routine.
The trial was based on an intention to treat principle and
was complied with the Declaration of Helsinki. The medical
ethical committees of the participating centers approved the
protocol. All patients gave written informed consent before
MPS.
The MERIDIAN trial was prematurely terminated
because of a too slow recruitment rate. Although the study was
now underpowered to test the hypothesis, no differences
between the treatment strategies were observed.
9 In view of the
lack of difference between the two treatment strategies, the
current analysis on the prognostic value of myocardial perfu-
sion defects ignores the differences in (randomized) treatment,
therefore all patients with reversible defects, including patients
who underwent revascularization and patients who were trea-
ted medically, were included in the analysis.
Study Population
Inclusion and exclusion criteria have previously been
described. In short patients C30 years with mild, stable
(C2 months) complaints of angina pectoris (CCS class I-II/IV)
and type 2 diabetes mellitus were eligible for screening.
Medical treatment was considered mandatory based upon the
symptomatic status of the patients. Type 2 diabetes mellitus
was deﬁned as having either one of the following: fasting
glucose of[7.0 mmol/L or non-fasting glucose[11.0 mmol/L
in 2 samples on 2 separate days; treatment with oral anti-
diabetic medication; treatment with insulin following initial
treatment with oral anti-diabetic medication; or onset of insulin
treatment at age C50 years.
All patients underwent initial clinical evaluation prior to
MPS. ECG-abnormalities were deﬁned as the presence of ST-T
abnormalities, Q-waves, T-wave inversion or left bundle
branch block. All patients were followed at the out-patient
clinic until January 1st, 2006, for the occurrence of cardiac
death and spontaneous, non-procedural related, non-fatal MI.
All deaths were considered cardiac unless an unequivocal non-
cardiac cause can be established. The events were indepen-
dently reviewed by the senior author (JP), who was not aware
of the patients treatment allocation and the MPS data. Myo-
cardial infarctions were deﬁned as CK MB levels greater than
or equal to twice the upper limit of normal. Procedural-related
infarctions were excluded from the analyses.
Myocardial Perfusion Scintigraphy
Stress and rest myocardial perfusion scintigraphy (with
single-photon emission computed tomography (SPECT)) was
performed with
99mTc labeled perfusion tracers (Tetrofosmin or
sesta-MIBI) or Thallium-201, according to the guidelines of the
American Society of Nuclear Cardiology.
10,11 The use of ECG-
gated SPECT was at the discretion of the nuclear physician.
Symptom limited exercise (bicycle or treadmill ergome-
try) was the preferred stress modality. Pharmacological
vasodilatory stress with adenosine or dipyridamole was applied
if there was insufﬁcient increase of heart rate (\85% age
predicted maximal heart-rate) during physical exercise, in the
presence of a left bundle branch block, or if the anti-anginal
medication had not been adequately discontinued
beforehand.
11
Dobutamine stress testing was performed in patients with
a contra-indication for adenosine or dipyridamole.
Image Analysis
Alocalpanelof2-3nuclearphysiciansanalyzedtheimages
using a 17 myocardial segment model. Segments were scored
with a 5-point scoring system (0 = normal; 1 = equivocal;
2 = moderate reduction; 3 = severe reduction; 4 = absent
activity). Summed stress score (SSS) and summed rest score
(SRS) were obtained by adding the scores of all segments of
stress and rest images, respectively. The summed difference
score (SDS) was calculated by subtracting the SRS from the
SSS. Reversible myocardial perfusion defects, indicative for
myocardial ischemia, were deﬁned as SDS C 3. The MPS out-
come for reversible defects was further categorized into: no
ischemia (SDS\3); moderate ischemia (SDS 3-7) and severe
ischemia(SDSof8orhigher(SDS C 8)).Fixeddefects(defects
also present at rest) were deﬁned as SRS C 3. Any perfusion
abnormality was deﬁned as SDS C 3 and/or SRS C 3.
12
Statistical Analysis
Data are presented as number of patients and proportion
or as mean ± standard deviation (SD). Continuous variables
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unpaired t test or Mann-Whitney test; categorical variables
were compared by v
2 or Fisher’s exact test where appropriate.
The annual event rates were calculated by dividing the
actual number of events by the total exposure years. Kaplan-
Meier cumulative survival rates were compared using the log-
rank test. Cox proportional hazards regression was used to
determine independent predictors of cardiac death or non-fatal
MI. Criterion for entry of variables into the multivariable
analysis was set on P B .2. The predictive value was expressed
as the hazard ratio (HR) with corresponding 95% conﬁdence
intervals (CI). The discriminating value of this model was
calculated by C-index. The SPSS package for windows version
12.0 (SPSS Inc, Chicago, IL, USA) was used for these pur-
poses. Values of P\.05 were considered statistically
signiﬁcant.
RESULTS
Baseline Characteristics
Between October 2002 and July 2004, 329 patients
were referred for MPS as part of the screening phase of
the MERIDIAN trial. Ten patients were excluded from
the present analysis because of crescendo angina pec-
toris during MPS (2), inconclusive MPS (2), or
withdrawal of consent (6). The remaining 319 patients
were eligible for the current analysis (Figure 1). One
patient, however, withdrew his consent after the ﬁrst
follow-up visit.
The baseline characteristics are described in
Table 1. The distribution of classical cardiac risk factors
was typical for a diabetic population. The mean duration
of diabetes was 8 years, and 38% of the patients were
insulin dependent. Almost half of patients (47%) had
documented coronary artery disease (PCI, MI or
CABG). Of all patients, 84% were on aspirin, 73% on
lipid-lowering therapy and 73% on beta-blockade.
MPS Results
Of 319 patients, 200 (63%) adequately performed
an exercise test, in 113 patients (36%) vasodilatory
stress was applied, and in 6 (2%) dobutamine stress test
was performed. In 290 (91%) patients
99mTc-labeled
perfusion tracers were used. Semi-quantitative scores
are described in Table 1. Perfusion abnormalities (ﬁxed
or reversible) were found in 208 (65%) patients; 60
(19%) had only ﬁxed defects, 78 (24%) mixed defects
and 70 (22%) patients had only reversible defects. Thus,
148 (46%) patients showed reversible perfusion defects;
85 (26%) patients had moderate and 63 (20%) severe
ischemia. These 148 patients were eligible for random-
ization into the MERIDIAN trial, 76 patients were
Figure 1. Study design.
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to continued pharmacological treatment.
Patients with reversible defects were older, pre-
dominantly male, had a higher prevalence of CCS II/IV,
and were less likely to have undergone PCI procedures.
Furthermore, these patients received more intensive
anti-anginal therapy and had more ECG-abnormalities
(Table 1).
Table 1. Clinical characteristics and myocardial perfusion scintigraphic parameters
All
patients
n 5 319
No
myocardial
ischemia
n 5 171
Myocardial
ischemia
n 5 148 P-value
Clinical characteristics
Male 201 (63) 93 (54) 108 (73) .001
Age (years) 65 (9) 64 (9) 66 (9) .04
CCS II/IV 130 (41) 61 (36) 69 (47) .05
Medical history (%)
Previous MI 92 (29) 43 (25) 49 (33)
Previous PCI 87 (27) 55 (32) 32 (22) .04
Previous CABG 56 (18) 30 (18) 26 (18)
Duration diabetes (years) 8 (7) 8 (7) 8 (7)
\5 years 119 (38) 62 (38) 57 (39)
[10 years 92 (30) 46 (28) 46 (31)
Insulin 122 (38) 67 (39) 55 (37)
Risk factors (%)
Hypertension 176 (55) 98 (57) 78 (53)
Smoking 56 (18) 26 (15) 30 (20)
Previous smoker 162 (51) 84 (49) 78 (53)
Family history 116 (36) 71 (42) 45 (30) .04
Hypercholesterolemia 201 (63) 108 (63) 93 (63)
Body mass index kg/m
2
(BMI)
29.4 (4) 30 (4) 29 (4)
Normal,\24.9 36 (11) 17 (10) 19 (13)
Obesitas, I[29.9 128 (40) 69 (41) 59 (40)
Drug therapy (%)
Aspirin 268 (84) 140 (82) 128 (87)
Statin 233 (73) 130 (76) 103 (70)
ACE-inhibition 130 (41) 74 (43) 56 (38)
Beta blockade 233 (73) 128 (75) 105 (71)
Long-acting nitrate 122 (38) 52 (30) 70 (47) .002
Calcium-antagonist 139 (44) 64 (37) 75 (51) .02
Insulin 122 (38) 67 (39) 55 (37)
ECG-abnormalities 158 (50) 72 (42) 86 (58) .004
MPS results
SSS 8 (8) 4.4 (6.8) 12.3 (6.8) \.001
SRS 4.3 (6) 3.9 (6.7) 4.8 (6.1)
SDS 3.7 (4.5) 0.4 (0.7) 7.5 (4.0) \.001
Any perfusion abnormality 208 (65) 60 (35) 148 (100)
At least one ﬁxed defect* 138 (43) 60 (35) 78 (53)
Values are presented as n (%) or as mean (SD) unless otherwise indicated.
CCS, Canadian Cardiovascular Society; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery
bypass grafting; ACE, angiotensin-converting enzyme; SSS, summed stress score; SRS, summed rest score; SDS, summed dif-
ference score.
*Also included patients with mixed defects: ﬁxed and reversible.
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A description of the coronary interventions per-
formed during follow-up, not including randomization
driven procedures, is presented here. Of the 148 patients
with reversible defects, the interventions are presented
in relation to the treatment strategies. During follow-up,
13 (8%) of the 171 patients without reversible defects
had an increase of their anginal complaints and under-
went elective, coronary angiography. Subsequent
revascularization was performed in 3 (2%) of these
patients. Furthermore, one patient underwent a rescue-
CABG after MI.
Of 72 patients with reversible myocardial perfusion
defects, randomized to continued pharmacological
treatment, 18 (25%) underwent elective coronary angi-
ography and 11 (15%) underwent subsequent
revascularization. In 3 patients (4%) with an acute MI a
primary PCI (2) or rescue-CABG (1) was performed.
One patient underwent a repeat PCI after 10 months for
in-stent restenosis.
All 76 patients assigned to early invasive treatment
underwent CAG. No or only non-signiﬁcant coronary
abnormalities were detected in 17 (23%) patients. In 3
patients (2 patients with single-vessel disease and 1
patient with multi-vessel disease) no intervention was
possible and 1 patient refused further treatment. Of the
remaining patients, 37 were referred for PCI and 18 for
CABG. One patient underwent repeat CABG 2 years
after the randomization-driven CABG. Furthermore, 1
patient underwent primary PCI for an acute MI, 9
months after the randomization-driven PCI.
Cardiac Events
A description of events per MPS category is pre-
sented in Table 2. The mean follow-up period of 148
patients with and 171 patients without reversible defects
was 2.2 ± 0.7 and 2.1 ± 0.6 years, respectively (min-
max: 2.3-38.5 months). During follow-up 3 of 171
(1.8%) patients without reversible defects, 3 of 83
patients with moderate ischemia and 8 of 65 patients
with severe ischemia on MPS had a non-fatal myocar-
dial infarction or died from a cardiac cause. The
differences in event rate between patients without and
patients with moderate or severe ischemia were statis-
tically signiﬁcant (P = .004).
Calculated annual event rates were 0.8 for patients
without defects, and 1.5 and 5.8 for patients with
respectively moderate and severe ischemia. Kaplan-
Meier curves for the occurrence of cardiac death or non-
fatal MI are shown in Figure 2. The pattern of the three
survival curves was preserved when the data were ana-
lyzed by randomized treatments (data not shown).
Variables Associated with the Occurrence
of the Combined Endpoint
The frequencies and hazard ratios of the different
clinical and diagnostic variables are shown in Table 3.
Table 2. The occurrence of events described per MPS category
Clinical
events
No myocardial ischemia
(SDS < 3)
Myocardial ischemia
(SDS ‡ 3) P-value*
No
defects
(n 5 111)
Only
ﬁxed
(n 5 60)
Total
(n 5 171)
Total
(n 5 148)
SDS 3-7
(n 5 85)
SDS ‡ 8
(n 5 63)
SDS
<3
vs
SDS
3-7
SDS
<3
vs
SDS
‡ 8
SDS
3-7
vs
SDS
‡ 8
Composite
events
1 (0.4) 2 (1.6) 3 (0.8) 11 (3.3) 3 (1.5) 8 (5.8) – \.001 .01
Cardiac death 0 (0) 1 (0.8) 1 (0.3) 7 (2.1) 2 (1.0) 5 (3.6) – .02 \.04
Non-fatal MI 1 (0.4) 1 (0.8) 2 (0.5) 7 (2.1) 2 (1.0) 5
# (3.6) – .01 –
Hospitalization
UAP
4 (1.6) 2 (1.6) 6 (1.6) 4 (1.2) 4 (2.0) 0 (0) – – –
All-cause
mortality
1 (0.4) 4 (3.1) 5 (1.4) 11 (3.2) 4 (2.0) 7 (4.9) – – –
All clinical events are described as n (annual event rate). Composite events taking account of the ﬁrst occurrence of cardiac death
or non-fatal MI.
MI, Myocardial infarction; UAP, unstable angina pectoris.
#One myocardial infarction was procedure related this MI was not considered as a cardiac event for the current analyses.
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(SDS C 8) (HR 5.45, 95%CI 1.89-15.71, P B .001), and
the use of insulin (HR 4.00, 95%CI 1.25-12.75, P B .02)
were independent predictors of cardiac death and non-
fatal MI. Previous myocardial infarction did not reach
statistical signiﬁcance as an independent predictor of
events (HR 2.93, 95% CI 0.99-8.78, P = .05). The
deviance (-2 log likelihood) of the model including
previous MI and insulin is 128.215. The change from the
previous (chi square) by adding MPS outcome is 11.363,
P\.001. The C-index of MPS outcome as a single
variable is 0.726, whereas the C-index of previous MI
and insulin use is 0.737. The combination MPS out-
come, previous MI and insulin use results in a C-index
of 0.838. We can conclude that the variable MPS out-
come therefore adds approximately 10% to the model.
DISCUSSION
In this study, we have shown that in almost 50% of
patients with type 2 diabetes mellitus and mild angina
pectoris myocardial ischemia is present. Secondly, we
have shown that severe myocardial ischemia is an
independent predictor for cardiac events. In addition to
the severity of myocardial ischemia, the use of insulin is
an independent predictor of cardiac death and non-fatal
MI. Patients without myocardial ischemia are at a low
annual risk, irrespective of the presence of ﬁxed defects
(0.4-0.8%).
Comparison with Previous Studies
Several reports have been published on the use of
MPS in diabetic patients.
5,6,8,13-15 One of these studies
Figure 2. Kaplan-Meier estimates of the cumulative rate of
cardiac death or non-fatal MI, related to the MPS outcome.
Kaplan-Meier cumulative event rates estimates for the occur-
rence of the cardiac death or non-fatal MI by the presence or
absence of myocardial perfusion defects. Black line =
SDS C 8; dark grey = SDS 3-7; light grey = SDS\3.
Cumulative curves according to the severity of myocardial
ischemia of all patients without myocardial ischemia compared
to all patients with reversible myocardial ischemia.
Table 3. Frequencies and hazard ratios of the occurrence of cardiac death or non-fatal MI according to
the presence of a characteristic
Characteristic Present Absent
Univariable Multivariable
P-value HR (95%) CI HR (95%) CI
Male gender 9/201 5/118 1.09 (0.36-3.25)
CCS II/IV 3/130 11/189 0.39 (0.11-1.38)
BMI C 29.9 kg/m
2 (n = 315) 8/128 6/187 1.71 (0.57-5.08)
Age 65 years or older 10/168 4/151 2.08 (0.64-6.74)
Previous MI 7/92 7/227 2.94 (0.99-8.75)*
Previous revascularization 7/121 7/198 1.63 (0.57-4.67)
Aspirin 14/268 0/51 26.53 (0.06-11990)
Statin 11/233 3/86 1.21 (0.33-4.41)
Insulin 10/122 4/197 4.25 (1.33-13.57)* 4.00 (1.25-12.75) .02
Abnormal rest ECG 11/158 3/161 3.44 (0.95-12.50)
 
MPS: Severe ischemia 8/63 6/256 5.70 (2.00-16.60)* 5.446 (1.89-15.71) B.001
Variables are described as the number of patients with the event in relation to the total amount of patients with this characteristic.
The variables: a history of MI, use of insulin and severe ischemia on MPS (SDS C 8) were entered in the Cox proportional hazards
model.
HR, Hazard ratio; CI, conﬁdence interval; LBBB, left bundle branch block; EF, ejection fraction; other abbreviations as described in
Table 1.
 P\.1; *P\.05 in the univariable analysis.
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they stated that ischemia was already present in 20% of
diabetics without any anginal complaint. However, both
the abovementioned study as well as others concerned
the value of MPS in asymptomatic diabetic patients, or
in symptomatic patients in whom the classiﬁcation of
anginal complaints was not provided. To our knowledge,
our study is the ﬁrst to assess the prognostic value of
MPS in patients with type 2 diabetes mellitus and well-
deﬁned, mild angina pectoris, CCS I-II/IV.
The presence of reversible defects on MPS is
associated with annual cardiac event rates ranging from
approximately 3% to 10%, in different diabetic popu-
lations.
7,8,14,16 Furthermore, recent MPS studies have
documented a positive relationship between the severity
and extent of the perfusion defect and the cardiac event
rate.
6,13,16-19 However, the abovementioned annual
event rates are lower than what one might expect based
on the early observations from the LIPID trial and the
study of Haffner et al, i.e. annual event rates were
estimated to be ±15-20%.
20,21 Our ﬁndings that type 2
diabetic patients with anginal complaints (CCS I-II/IV)
and severe reversible defects have a 3-6 fold higher
annual event are in line with more recent studies.
22,23
Signiﬁcance of a Normal MPS
Inthe general population anormalMPS isassociated
with a low annual event rate of B1%.
17 The prognostic
value of a normal MPS in type 2 diabetic patients has not
yet been crystallized completely. Some of the afore-
mentioned studies reported low cardiac event rates for
patients with a normal MPS (1.2-2%), although higher
eventratesof2.5-3%werealsodescribed.
7,8,13,16,24These
higher rates might be explained by the different popula-
tions studied: the use of insulin, inability to perform
exercise-stress testing and the severity of complaints.
Awareness regarding the MPS deﬁnitions used is of
importance when comparing event rates. Many investi-
gators use a SSS \ 4 to deﬁne a normal MPS. In this
study, we focused on reversible defects, using SDS\3
to deﬁne a non-ischemic MPS. This deﬁnition resulted
in an annual event rate of 0.8%. A SDS\3, however,
does not rule out the presence of ﬁxed defects and it
therefore might lead to an overestimation of the event
rate. The annual event rate of a clinical normal MPS
(SDS\3 and SRS\3) was indeed lower (0.4%).
Irrespective of the cut-off value used for normality,
our favorable prognostic result of a normal MPS is
comparable with event rates in the general population.
This low event rate might be ampliﬁed by the fact that at
time of screening, a high percentage of patients received
risk modifying medication. Secondly, patients with an
LVEF \ 35% were excluded from the study. An
impaired LVEF is a well-known prognostic factor.
25 The
exclusion of patients with an LVEF \ 35% might
therefore have resulted in a lower event rate.
It has been suggested that the ‘warrantee’ period of
a normal MPS in diabetics has a maximum of 2 years,
after which the event rates will start to increase rap-
idly.
8,18 The follow-up period of our population was too
short to conﬁrm or contradict this hypothesis.
Insulin Use and Incidence of Cardiac Events
In our study, the use of insulin was independently
related to the occurrence of cardiac events. This ﬁnding
is in line with several other studies, all concluding that
patients requiring insulin are more likely to develop
adverse events.
20,26,27 This is most likely due to a more
advanced state of diabetes and its related morbidity,
including atherosclerosis. However, no relation was
found with the duration of diabetes mellitus. This lack of
relation might be explained by the fact that the majority
of patients are diagnosed years after onset of the glu-
cometabolic abnormalities, thereby negatively
inﬂuencing the power of this variable.
28
Previous Myocardial Infarction and
Incidence of Cardiac Events
Previous myocardial infarction negatively inﬂu-
ences outcome in both diabetic and non-diabetic patients.
However, in our population this relation did not reach our
beforehand deﬁned level of signiﬁcance (P\.05). This
is most likely due to sampling of the population.
LIMITATIONS
The premature discontinuation of the MERIDIAN
trial resulted in a lower number of patients and a shorter
follow-up period and consequently a low number of
events. Furthermore, the current study was based on a
pre-speciﬁed population with different treatment strate-
gies; it is possible that the randomization has interfered
with the outcome of the MPS-related cardiac event rate.
However, no differences between the treatment strate-
gies were observed in the MERIDIAN trial, and a recent
study has found similar results in approximately 3,000
non-diabetic patients with stable coronary artery disease
and evidence of myocardial ischemia.
29
Theoretically there is a substantial chance of
detecting spurious associations with the multivariable
analysis described in this article; however, the outcome
of this analysis conﬁrms the results of previous studies
in which these variables were also found to be inde-
pendent predictors of cardiac death.
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In our study, we found that type 2 diabetic patients
with only mild anginal complaints present with a wide
range of reversible perfusion defects on MPS. Patients
with severe myocardial ischemia are at a 3-6 times higher
risk of cardiac death and non-fatal MI compared to
patients without or with moderate myocardial ischemia.
The incidence of cardiac events in the patients with no or
moderate ischemia, irrespective of the presence of ﬁxed
defects, is much lower than would have been expected
based on previous studies. These ﬁndings are line with
those of Hachamovitch et al.
17 This implies that the
amount ischemia determines appropriate therapeutic
strategies. It is conceivable that these patients with no or
moderate ischemia, conform their non-diabetic counter-
parts, will not beneﬁt from an invasive approach and
subsequent revascularization. Consequently it seems
more reasonable to focus on life-style advices, optimized
pharmacological therapy and close surveillance of
symptoms. However, in patients with severe ischemia, a
more aggressive and invasive approach seems justiﬁed.
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